Actively Recruiting
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
Led by University of California, San Francisco · Updated on 2026-01-07
48
Participants Needed
1
Research Sites
135 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.
CONDITIONS
Official Title
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Heart rate less than 105 beats per minute
- Systolic blood pressure between 90 and 160
- Diastolic blood pressure between 50 and 100
- Body Mass Index (BMI) of 38.0 or less
- Current regular cannabis user who smokes or vapes at least three days per week for the past 3 months or more
- Positive urine test for THC and self-report of cannabis use
- Current daily user of inhaled tobacco or nicotine products for the past 3 months or more
- Saliva cotinine level of 30 ng/mL or higher
You will not qualify if you...
- Unstable medical conditions including heart disease, seizures, cancer, uncontrolled thyroid disease, diabetes, hepatitis B or C, liver disease, glaucoma, kidney disease, urinary retention, recent ulcer, or active use of inhalers for asthma/COPD
- Uncontrolled hypertension not under treatment
- Alcohol or illicit drug dependence within the past 12 months (except recent completion of treatment)
- Positive toxicology test at screening (except THC and prescribed medications)
- Use of opioid replacement therapy
- Current or past schizophrenia or bipolar disorder
- Major depression currently or within the past year
- Major personality disorder
- Use of psychiatric medications except certain antidepressants if stable
- Immunodeficiency disorders or chronic diseases affecting immunity
- Traumatic brain injury
- Recent or worsening cough, fever, or abdominal symptoms within two weeks
- Use of medications that induce nicotine metabolism or concurrent nicotine medications
- Use of stimulant medications like Adderall
- Chronic health problems such as oral thrush or fainting
- Pregnancy or breastfeeding
- Participation in another clinical trial
- Inability to communicate in English
- History of marijuana-induced psychosis or paranoia
- High severity of cannabis dependence (SDS score 7 or higher)
- Planning to quit smoking or vaping tobacco or cannabis within 60 days
- Uncomfortable with blood draws
- Unable to abstain from tobacco and cannabis use for 13 hours before visits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zuckerberg San Francisco General Hospital
San Francisco, California, United States, 94110
Actively Recruiting
Research Team
A
Armando Barraza
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here